This hybrid (also called a practical or embedded trial) will involve 30 ADS sites located across the U.S. that will be randomized into two groups: 15 ADS programs will serve as treatment sites and provide ADS services as usual and the ADS Plus intervention; 15 ADS programs will serve as the control condition and will provide ADS as usual. Prior to randomization, the investigators will carefully examine sites on important variables such as size or capacity, location (urban, suburban, rural), percent of participants with a dementia diagnosis, staff to client ratio, ownership structure, and how long each center has been operating. The investigators will then implement re-randomization techniques to ensure optimal balance between ADS Plus and control sites on these site-level factors. Each of 30 sites will enroll 15-23 CGs in the study, with the expectation that an average of 10 per site will be retained at 6 months (43% attrition projected based on ADS Plus pilot and other CG trials). This will yield a total of 300 retained participants (150 CGs in ADS Plus sites; 150 in ADS usual care sites) over a 2 year recruitment period. In accordance with the translational focus, the inclusion criteria are purposely broad to reflect the real world case mix of CGs using ADS such that any CG with an older relative (>60 years) upon initial intake and enrollment in a participating ADS will be eligible for study inclusion. Each of 30 ADS sites will designate a staff member to serve as research liaison for that site and participate in 4 hours of paid training (via webinar). Research liaisons will be responsible for informing CGs (at initial intake) of the study using Johns Hopkins University (JHU) approved Institutional Review Board (IRB) scripts, recruitment letters and flyers. The Research liaisons will provide a packet of study materials that will contain a copy of the consent form, study flyer, study letter, consent to contact sheet. CGs expressing study interest will sign an IRB approved form to agree to be contacted by study staff. Caregivers will receive a telephone call from a JHU research interviewer. The interviewer will explain study procedures, review the consent form that the caregiver has been provided in the packet. If the caregiver is interested the staff will obtain verbal assent and instruct the caregiver to sign the consent form with the date and time. If the CG is eligible and has signed the consent and provided verbal assent a 45 minute baseline interview will be conducted either immediately or at a time convenient for the CG yet within 1 week of screening. The consent form will then be returned to the ADS site and scanned or faxed to JHU study staff. In previous trials, the investigators found CGs can attend to an hour by telephone.